Hey there, bargain hunter. Most of the MedTech conversation this earnings season has been about Abbott’s breakout and the GLP-1 effect on device volumes. Boston Scientific barely gets mentioned. Which is either a problem or an opening, depending on how you read the data.

Boston Scientific Corporation enters the second half of 2026 under considerable pressure. The stock has retreated roughly 60% from its September 2025 peak of $109.50. That is not a modest pullback. That is the kind of move that either signals a business in real trouble, or a mispricing that has run further than the fundamentals justify.

July 29 is when we find out which one it is.

What Actually Happened

The selloff started with Q4 2025 guidance. Boston Scientific generated Q4 2025 net sales of $5.286 billion and adjusted EPS of $0.80. Sales increased 15.9% on a reported basis. Solid, right? Then management issued 2026 guidance that underwhelmed, and the stock dropped about 17.6% in a single session.

It never fully recovered.

A separate earnings update saw management cut 2026 guidance amid weakness in WATCHMAN, Electrophysiology, and Urology, while expressing confidence that upcoming product launches could support results in 2027 and 2028.

That is a real tension to sit with. The near term is messy. The long term, if management is right, looks very different.

The Products Under the Microscope

WATCHMAN is the biggest concern. It is the company’s flagship cardiac left atrial appendage closure device, used to reduce stroke risk in patients with non-valvular atrial fibrillation. It was supposed to be a multi-year growth driver.

Management has indicated that more WATCHMAN implants are being bundled with other cardiac procedures, and the CEO has flagged an expectation of flat dollar growth from Q1 to Q2 2026 and likely into Q3 2026. Bundling sounds benign. What it actually means is slower standalone growth and harder comps.

There have also been device actions. In June 2026, Boston Scientific was reported as dropped from the Russell 3000 Growth Benchmark and initiated a Class II recall (FDA: “Class 2”) of Orca Sterile, Single Use Air/Water and Suction Valves after reports of the suction button sticking. A Class II recall is typically a non-life-threatening quality issue. It is not an existential event. But stacked on top of guidance cuts, it keeps the sentiment negative.

More recently, the FDA listed a Class 2 recall for certain batches of Boston Scientific’s Coyote” Over-the-Wire (OTW) Percutaneous Transluminal Angioplasty (PTA) Balloon Dilatation Catheter devices due to potential inflation/deflation difficulty during use. Another headline, another excuse for institutions to stay away.

The Numbers for July 29

Boston Scientific is slated to report second quarter 2026 results on July 29, before the market opens.

The company beat or matched earnings estimates in each of the last four reported quarters. The Q1 2026 earnings report delivered $0.80 in adjusted EPS on $5.203 billion in revenue, and organic growth of 9.4% (operational and organic) exceeded guidance despite emerging headwinds.

That is a company still growing. Through recalls. Through guidance cuts. Through a 60% drawdown.

The Valuation Case

This is where the story gets genuinely interesting for a value-focused investor.

Boston Scientific stock is coming off a difficult stretch, with the share price down sharply from its 52-week high. Claims about the stock’s exact trailing one-year return, its current P/E, PEG ratio, and industry/peer valuation averages vary significantly by data source and change daily, so treat any point-in-time multiples as snapshots rather than constants.

There is also some insider conviction worth noting. The board authorized a $5 billion share repurchase program, and the company entered into a $2 billion accelerated share repurchase agreement in May as part of that authorization.

Bull / Base / Bear

Bull: July 29 beats on revenue and EPS. WATCHMAN shows any sequential improvement. Management raises the back-half guidance range. Institutions re-enter. The stock starts a recovery toward $60.

Base: Q2 meets estimates, guidance stays cautious but stable. The stock consolidates in the $42 to $50 range through year-end.

Bear: Q2 misses or another guidance cut. WATCHMAN growth stays flat. The 60% drawdown becomes 65% to 70%. The product diversification story takes longer to rebuild credibility.

The Cheap Investor Scorecard

• Stock vs. 52-week high: down approximately 60%. The discount is significant.
• Q1 2026 organic revenue growth: 9.4%, above guidance. Growth is not dead.
• Board buyback: $5 billion authorized.
• Key risk: WATCHMAN franchise growth, recall frequency, and guidance credibility.
• Management lowered its full-year organic revenue growth outlook to 6.5% to 8%, and expects full-year adjusted EPS of $3.34 to $3.41. The bar is lower now. That is not always a bad thing.

The bear case on BSX is real. The recalls are real. The WATCHMAN slowdown is real. But a 60% drawdown on a company still growing organically, with a $5 billion buyback, is a setup worth watching closely.

July 29 does not need to be a blowout. It just needs to stop the bleeding. If it does, this stock has a long way to reclaim.